Rituximab – CRI Report

Investigation Report on China’s Rituximab Market 2021-2025

admin — Fri, 23 Apr 2021 13:03:00 +0000

Rituximab is a monoclonal antibody to target cells that have the CD20 marker on their surface. It is mainly used to treat diseases caused by excessive B lymphocytes, including lymphoma, chronic lymphocytic leukemia, transplantation rejection, and certain autoimmune diseases. The original drug was developed by Roche. Rituximab was launched in China in 2000. In 2020, besides Roche and its subsidiary corporation, Genentech, another main manufacturer in the Chinese market is Shanghai Henlius.

According to CRI’s market research, the sales revenue of Rituximab in the Chinese market in 2016-2019 has an increase trend. The sales revenue of Rituximab in China increases from CNY943 million in 2016 to CNY1.42 billion in 2019. The sales value of Rituximab in China was approximately CNY1.3 billion in 2020. It decreased 8.4% Year on Year. The reason for the sales decline is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Rituximab in China is 8.4% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Rituximab will have a recovery growth from 2021 to 2025. In addition, the sales will also increase due to the market expansion. Compared to indications approved in some developed countries, Rituximab has fewer indications being approved in China. The only two approved indications are non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Thus, the possibility of increase number of indications may bring new target patients for Rituximab. Besides, with the emergence of biosimilar drugs, Roche was no longer the monopoly in the Chinese Rituximab market. As a result, the price of Rituximab will be more affordable in the future, which will lead to an increase in sales volume.

Topics Covered:
-The impact of COVID-19 on China’s Rituximab market
– Sales value and volume of China’s Rituximab 2016-2020
– Competitive landscape of China’s Rituximab market
– Prices of Rituximab in China
– Prices of Rituximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Rituximab market
– Prospect of China’s Rituximab market from 2021 to 2025

The post Investigation Report on China’s Rituximab Market 2021-2025 first appeared on CRI Report.

Investigation Report on Chinese Rituximab Market, 2020-2024

admin — Tue, 20 Oct 2020 02:29:44 +0000

Description
Rituximab (Roche’s trade name: MabThera/Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc. In Sep 2019, FDA approved Roche’s rituximab in combination with glucocorticoids for treating granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) disorders.
The global sales of rituximab have been very mature. In the year of 2019, Rituximab recorded a revenue of US$6.7 billion. The drug was mostly used for tumor treatment.
In China, Roche’s Rituximab is mainly used to treat non-Hodgkin lymphoma. As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin’s disease in China. The incidence of non-Hodgkin’s lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 60 cases per 1 million people in 2019.
On December 10, 2019, Roche announced that its Rituxan/MabThera, (rituximab) has been formally approved by the National Medical Products Administration (NMPA) of China for the initial treatment of follicles Monotherapy for patients with lymphoma (FL) who have achieved complete or partial remission after rituximab combined with chemotherapy, and combined treatment with fludarabine and cyclophosphamide (FC) for previously untreated or relapsed/refractory Patients with chronic lymphocytic leukemia (CLL).
According to CRI’s market research, in 2019, the sales value of Rituximab reached CNY1.42 billion(US$206 million) in China.
According to CRI’s market research, by the end of 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech.
However, starting in 2019, Shanghai Henlius Biotech, Inc.’s rituximab (trade name: Hanlikang) began to be listed on the Chinese market. According to sales in 2019, Roche and Genentech’s rituximab products accounted for approximately 98% of the Chinese market, and the corporate market share was occupied by Shanghai Henlius Biotech, Inc.
According to CRI’s market research, it is expected that with the launch of more domestic rituximab products in China, the market share of Roche and Genentech will continue to decline in 2020-2024. But for a long period of time, Roche and Genentech will still occupy the major market share of rituximab in China.

Topics Covered:
-Development environment of Chinese Rituximab market
-Sales value and volume of Rituximab in China 2015-2019
-Sales value and volume of Rituximab in Different Regions of China 2015-2019
-Prices of Rituximab in China 2015-2019
-Prices of Roche’s Rituximab(MabThera/ Rituxan) in Different Regions of China 2015-2019
-Prices of Shanghai Henlius Biotech, Inc.’s Rituximab(Hanlikang) in Different Regions of China 2015-2019
-Progress of generic Rituximab in China
-Prospects of Chinese Rituximab Market, 2020-2024

The post Investigation Report on Chinese Rituximab Market, 2020-2024 first appeared on CRI Report.

Sample of Investigation Report on Chinese Rituximab Market, 2018-2022

admin — Fri, 11 Jan 2019 08:29:58 +0000

This is a free sample of the report

Investigation Report on Chinese Rituximab Market, 2018-2022

The post Sample of Investigation Report on Chinese Rituximab Market, 2018-2022 first appeared on CRI Report.

Investigation Report on Chinese Rituximab Market, 2018-2022

admin — Fri, 17 Aug 2018 09:04:57 +0000

Description
Rituximab (Roche’s trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc.
The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche’s Rituximab is mainly used to treat non-Hodgkin lymphoma.
As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin’s disease in China. The incidence of non-Hodgkin’s lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Autoimmune diseases may affect organs such as the central nervous system, lungs, liver and kidneys, cause dysfunction or even failure of organs, and ultimately threaten life. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.
According to CRI, by Jul. 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.

Topics Covered:
– Development environment of Chinese Rituximab market
– Sales of Rituximab in China
– Prices of Rituximab in China
– Progress of generic Rituximab in China
– Prospects of Chinese Rituximab Market, 2018-2022

Table of Contents
1 Basic Concepts of Rituximab
1.1 Indications for Rituximab
1.2 Development History of Rituximab in China
1.3 Governmental Approval of Rituximab in China

2 Sales of Rituximab in China, 2013-2017
2.1 Sales Value of Rituximab
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Volume of Rituximab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Parts of China
2.3 Sales of Rituximab by Dosage Form

3 Major Rituximab Manufacturers in China, 2013-2017
3.1 Market Share of Major Rituximab Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Roche
3.2.1 Enterprise Profile
3.2.2 Sales of Roche’s Rituximab in China
3.3 Genentech
3.3.1 Enterprise Profile
3.3.2 Sales of Genentech’s Rituximab in China

4 Prices of Rituximab in China, 2017-2018
4.1 Average Prices of Rituximab in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers’ Rituximab in China
4.2.1 Price of Roche’s Rituximab in China
4.2.2 Price of Genentech’s Rituximab in China

5 Prospects of Chinese Valsartan Market, 2018-2022
5.1 Factors Influencing Rituximab Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern

Selected Charts
Chart Rituximab Products Approved to Market in China by 2018
Chart Sales Value of Rituximab in China, 2013-2017
Chart Sales Value of Rituximab by Region in China, 2013-2017
Chart Market Share of Rituximab Manufacturers by Sales Value in China, 2013-2017
Chart Prices of Roche’s Rituximab in Key Regions of China, 2017-2018
Chart Prices of Genentech’s Rituximab in Key Regions of China, 2017-2018
Chart Forecast on Sales of Rituximab in China, 2018-2022
Chart Generic Rituximab in China

The post Investigation Report on Chinese Rituximab Market, 2018-2022 first appeared on CRI Report.